File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Distinct tumour specificity and IL-7 requirements of CD56 - and CD56 + subsets of human γδ T cells

TitleDistinct tumour specificity and IL-7 requirements of CD56 - and CD56 + subsets of human γδ T cells
Authors
Issue Date2001
PublisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/SJI
Citation
Scandinavian Journal of Immunology, 2001, v. 53 n. 1, p. 40-48 How to Cite?
Abstractγδ T cells are believed to recognize tissue injury caused by infections, tumours, as well as chemical and physical agents. The present study was carried out to study the feasibility of the ex vivo expansion of γδ T cells from healthy individuals, and to determine their functional capacity against tumours. We selectively expanded the peripheral γδ T cells of five donors against a myeloma cell line, XG-7. Under optimal conditions, the resulting bulk cultures comprised about 82% of the γδ T cells, more than 90% of which showed the T-cell receptor (TCR)-Vγ9δ2 rearrangement. These γδ T-cell cultures exhibited TCR-γδ dependent cytotoxicity against different tumour cell lines including Molt-4, BJAB, Epstein-Barr virus (EBV) transformed lymphoid cell lines (LCL), and the nasopharyngeal carcinoma (NPC) cell lines, CNE2 and 915, in addition to the stimulator XG-7. By competitive cytotoxicity assays, the γδ T cells demonstrated recognition of at least three distinct target specificities expressed by Molt-4, CNE2 and LCL. respectively, which were related to that expressed by the stimulator XG-7 cells. The recognition of the specificity expressed by XG-7 and Molt-4 was further shown to require the participation of heat shock protein (HSP). The specificity expressed by CNE2 and 915 was preferentially recognized by the CD56- subset of γδ T cells, which could be sustained in the presence of interleukin (IL)-7. These results suggested that γδ T-cell immunity against tumour cell lines may be acquired in response to other types of tissue injury and, hence, implicates a role for their use in the prevention and treatment of tumours.
Persistent Identifierhttp://hdl.handle.net/10722/157332
ISSN
2023 Impact Factor: 4.1
2023 SCImago Journal Rankings: 0.946
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorZheng, Ben_US
dc.contributor.authorLam, Cen_US
dc.contributor.authorIm, Sen_US
dc.contributor.authorHuang, Jen_US
dc.contributor.authorLuk, Wen_US
dc.contributor.authorLau, SYen_US
dc.contributor.authorYau, KSen_US
dc.contributor.authorWong, CKen_US
dc.contributor.authorYao, Ken_US
dc.contributor.authorNg, MHen_US
dc.date.accessioned2012-08-08T08:48:59Z-
dc.date.available2012-08-08T08:48:59Z-
dc.date.issued2001en_US
dc.identifier.citationScandinavian Journal of Immunology, 2001, v. 53 n. 1, p. 40-48en_US
dc.identifier.issn0300-9475en_US
dc.identifier.urihttp://hdl.handle.net/10722/157332-
dc.description.abstractγδ T cells are believed to recognize tissue injury caused by infections, tumours, as well as chemical and physical agents. The present study was carried out to study the feasibility of the ex vivo expansion of γδ T cells from healthy individuals, and to determine their functional capacity against tumours. We selectively expanded the peripheral γδ T cells of five donors against a myeloma cell line, XG-7. Under optimal conditions, the resulting bulk cultures comprised about 82% of the γδ T cells, more than 90% of which showed the T-cell receptor (TCR)-Vγ9δ2 rearrangement. These γδ T-cell cultures exhibited TCR-γδ dependent cytotoxicity against different tumour cell lines including Molt-4, BJAB, Epstein-Barr virus (EBV) transformed lymphoid cell lines (LCL), and the nasopharyngeal carcinoma (NPC) cell lines, CNE2 and 915, in addition to the stimulator XG-7. By competitive cytotoxicity assays, the γδ T cells demonstrated recognition of at least three distinct target specificities expressed by Molt-4, CNE2 and LCL. respectively, which were related to that expressed by the stimulator XG-7 cells. The recognition of the specificity expressed by XG-7 and Molt-4 was further shown to require the participation of heat shock protein (HSP). The specificity expressed by CNE2 and 915 was preferentially recognized by the CD56- subset of γδ T cells, which could be sustained in the presence of interleukin (IL)-7. These results suggested that γδ T-cell immunity against tumour cell lines may be acquired in response to other types of tissue injury and, hence, implicates a role for their use in the prevention and treatment of tumours.en_US
dc.languageengen_US
dc.publisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/SJIen_US
dc.relation.ispartofScandinavian Journal of Immunologyen_US
dc.rightsScandinavian Journal of Immunology. Copyright © Blackwell Publishing Ltd.-
dc.subject.meshAntigens, Cd56 - Analysisen_US
dc.subject.meshBurkitt Lymphoma - Immunology - Pathologyen_US
dc.subject.meshCarcinoma - Immunology - Pathologyen_US
dc.subject.meshCells, Cultureden_US
dc.subject.meshCytokines - Pharmacologyen_US
dc.subject.meshCytotoxicity Tests, Immunologicen_US
dc.subject.meshCytotoxicity, Immunologicen_US
dc.subject.meshDrug Synergismen_US
dc.subject.meshFeasibility Studiesen_US
dc.subject.meshHumansen_US
dc.subject.meshImmunotherapy, Adoptiveen_US
dc.subject.meshInterleukin-2 - Pharmacologyen_US
dc.subject.meshInterleukin-7 - Pharmacology - Physiologyen_US
dc.subject.meshLeukemia-Lymphoma, Adult T-Cell - Immunology - Pathologyen_US
dc.subject.meshLymphocyte Activationen_US
dc.subject.meshMultiple Myeloma - Immunology - Pathologyen_US
dc.subject.meshNasopharyngeal Neoplasms - Immunology - Pathologyen_US
dc.subject.meshNeoplasms - Immunology - Pathologyen_US
dc.subject.meshReceptors, Antigen, T-Cell, Gamma-Delta - Analysisen_US
dc.subject.meshRecombinant Proteins - Pharmacologyen_US
dc.subject.meshT-Lymphocyte Subsets - Drug Effects - Immunologyen_US
dc.subject.meshTumor Cells, Cultured - Immunologyen_US
dc.titleDistinct tumour specificity and IL-7 requirements of CD56 - and CD56 + subsets of human γδ T cellsen_US
dc.typeArticleen_US
dc.identifier.emailZheng, B: bzheng@hkucc.hku.hken_US
dc.identifier.emailIm, S: swkim@hkucc.hku.hk-
dc.identifier.emailNg, MH: hrmmnmh@hkucc.hku.hk-
dc.identifier.authorityZheng, B=rp00353en_US
dc.description.naturelink_to_OA_fulltexten_US
dc.identifier.doi10.1046/j.1365-3083.2001.00827.xen_US
dc.identifier.pmid11169205-
dc.identifier.scopuseid_2-s2.0-0035154722en_US
dc.identifier.hkuros61948-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0035154722&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume53en_US
dc.identifier.issue1en_US
dc.identifier.spage40en_US
dc.identifier.epage48en_US
dc.identifier.isiWOS:000166794100006-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridZheng, B=7201780588en_US
dc.identifier.scopusauthoridLam, C=7402989860en_US
dc.identifier.scopusauthoridIm, S=22943859000en_US
dc.identifier.scopusauthoridHuang, J=7407189939en_US
dc.identifier.scopusauthoridLuk, W=7005237837en_US
dc.identifier.scopusauthoridLau, SY=7401596375en_US
dc.identifier.scopusauthoridYau, KS=7101941406en_US
dc.identifier.scopusauthoridWong, CK=13310337300en_US
dc.identifier.scopusauthoridYao, K=22945907500en_US
dc.identifier.scopusauthoridNg, MH=7202076421en_US
dc.customcontrol.immutablesml 130529-
dc.identifier.issnl0300-9475-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats